Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer's disease variants: AβPParc and PSEN1DE9.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
29
02
2020
accepted:
08
06
2020
revised:
04
06
2020
pubmed:
26
6
2020
medline:
3
2
2022
entrez:
26
6
2020
Statut:
ppublish
Résumé
Autosomal-dominant Alzheimer's disease (ADAD) may be associated with atypical amyloid beta deposits in the brain. In vivo amyloid imaging using
Identifiants
pubmed: 32581318
doi: 10.1038/s41380-020-0817-2
pii: 10.1038/s41380-020-0817-2
pmc: PMC8758475
doi:
Substances chimiques
Amyloid
0
Amyloid beta-Peptides
0
Aniline Compounds
0
PSEN1 protein, human
0
Presenilin-1
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5609-5619Informations de copyright
© 2020. The Author(s).
Références
Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, Axelman K, et al. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol. 2008;65:499–505.
doi: 10.1001/archneur.65.4.499
Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer’s disease. Lancet Neurol. 2013;12:92–104.
doi: 10.1016/S1474-4422(12)70259-4
Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, et al. A variant of Alzheimer’s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med. 1998;4:452–5.
doi: 10.1038/nm0498-452
Mann DM, Takeuchi A, Sato S, Cairns NJ, Lantos PL, Rossor MN, et al. Cases of Alzheimer’s disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic beta-amyloid pathology known as ‘cotton wool’ plaques. Neuropathol Appl Neurobiol. 2001;27:189–96.
doi: 10.1046/j.1365-2990.2001.00316.x
Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D, et al. The Arctic AbetaPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Abeta. Acta Neuropathol Commun. 2013;1:60.
doi: 10.1186/2051-5960-1-60
Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79:229–36.
doi: 10.1212/WNL.0b013e31825fdf18
Dahlgren KN, Manelli AM, Stine WB Jr., Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046–53.
doi: 10.1074/jbc.M201750200
Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4:887–93.
doi: 10.1038/nn0901-887
Philipson O, Lord A, Lalowski M, Soliymani R, Baumann M, Thyberg J, et al. The Arctic amyloid-beta precursor protein (AbetaPP) mutation results in distinct plaques and accumulation of N- and C-truncated Abeta. Neurobiol Aging. 2012;33:1010.e1–13.
doi: 10.1016/j.neurobiolaging.2011.10.022
Thordardottir S, Kinhult Stahlbom A, Almkvist O, Thonberg H, Eriksdotter M, Zetterberg H, et al. The effects of different familial Alzheimer’s disease mutations on APP processing in vivo. Alzheimers Res Ther. 2017;9:9.
doi: 10.1186/s13195-017-0234-1
Thordardottir S, Stahlbom AK, Ferreira D, Almkvist O, Westman E, Zetterberg H, et al. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer’s disease. J Alzheimers Dis. 2015;43:1393–402.
doi: 10.3233/JAD-140339
Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen JP, Viitanen M, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer’s disease. Brain. 2008;131:1845–53.
doi: 10.1093/brain/awn107
Falcon B, Zhang W, Schweighauser M, Murzin AG, Vidal R, Garringer HJ, et al. Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a common fold. Acta Neuropathol. 2018;136:699–708.
doi: 10.1007/s00401-018-1914-z
Verkkoniemi A, Kalimo H, Paetau A, Somer M, Iwatsubo T, Hardy J, et al. Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol. 2001;60:483–92.
doi: 10.1093/jnen/60.5.483
Lemoine L, Saint-Aubert L, Nennesmo I, Gillberg PG, Nordberg A. Cortical laminar tau deposits and activated astrocytes in Alzheimer’s disease visualised by (3)H-THK5117 and (3)H-deprenyl autoradiography. Sci Rep. 2017;7:45496.
doi: 10.1038/srep45496
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112–34.
doi: 10.1038/s41380-018-0342-8
Murugan NA, Halldin C, Nordberg A, Langstrom B, Agren H. The culprit is in the cave: the core sites explain the binding profiles of amyloid-specific tracers. J Phys Chem Lett. 2016;7:3313–21.
doi: 10.1021/acs.jpclett.6b01586
Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain. 2013;136:2217–27.
doi: 10.1093/brain/awt142
Ni R, Gillberg PG, Bogdanovic N, Viitanen M, Myllykangas L, Nennesmo I, et al. Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer’s disease. Alzheimers Dement. 2017;13:419–30.
doi: 10.1016/j.jalz.2016.08.006